Breast cancer progresses when over-expressed estrogen receptors (ER) increase transcriptional activity.[3] Treatment of advanced metastatic disease, therefore, will try to reduce circulating estrogens using aromatase inhibitors or block the receptors using selective ER modulators. This evidence concerns the gene ESR1 and breast carcinoma.